Immunocore Holdings (IMCR) Capital Expenditures (2023 - 2026)

Immunocore Holdings has disclosed Capital Expenditures across 4 years of filings, most recently posting $1.8 million for Q1 2026.

• Capital Expenditures for Q1 2026 came in at $1.8 million, up 497.65% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.8 million (up 15.51% YoY), and the FY2025 annual result was $4.3 million, down 16.1% from the prior year.
• Capital Expenditures came in at $1.8 million for Q1 2026 at Immunocore Holdings, down from $2.9 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $3.6 million in Q4 2024 to a low of $212000.0 in Q3 2023.
• The 4-year median for Capital Expenditures is $817000.0 (2023), against an average of $1.3 million.
• Across the five-year window, Capital Expenditures slumped 85.67% in 2024 and soared 497.65% in 2026, its largest moves.
• Immunocore Holdings' Capital Expenditures stood at $817000.0 in 2023, then soared by 338.68% to $3.6 million in 2024, then slipped by 19.64% to $2.9 million in 2025, then tumbled by 38.16% to $1.8 million in 2026.
• The last three Capital Expenditures figures came in at $1.8 million (Q1 2026), $2.9 million (Q4 2025), and $748000.0 (Q3 2025), per Business Quant data.